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1. Introduction
During the past decade, the knowledge of clinical course and management of hepatitis C virus
(HCV) infection has increased enormously, but there are few data on the course of the disease
and its treatment in the elderly population (age > 60 years). According to its epidemiology, we
are now facing HCV infection from the 20th century. We must take into account that in contrast
to a younger population, old people who will develop Chronic C Hepatitis will be mainly
women with genotype 1 and more severe fibrosis as clinical presentation pattern.
Thus, chronic infection is prevalent and may be severe in older population. Moreover, aging
is an adverse factor for liver disease progression and treatment outcome.
2. Hepatitis C in elderly
Among younger people HCV infection declines [1]. HCV infections are common worldwide.
It is estimated that about 3% of the world’s population have HCV. There are about 4 million
carriers in Europe alone. The prevalence of HCV in the general population varies widely across
European countries, with ranges from 0.4% in Sweden, Germany and the Netherlands to over
20% in one region of Italy. According to an American National Health survey, the prevalence
of HCV infection in elderly population varies from 0,9 % to 1.0% in subjects who were,
respectively, in the age groups of 60-69 years and 70 years and more [2]. In general, countries
in the southern part of Europe have a higher HCV prevalence compared to countries in the
north or west of the EU. Italy in particular has a high general population prevalence of HCV,
much higher than the country’s estimated HBV prevalence [3]. In a large Italian study
conducted among 1646 subjects, seroprevalence of HCV antibodies were found between 5%
and 2% in patient ranging respectively, 58 to 67 years and 68 to 77 years [4].
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Epidemiologic and phylogenetic assessments suggest this is caused by a period of increased
iatrogenic transmission that took place around the 1960s due to the exposure to blood or blood
products mainly deriving from using of non-disposable syringe [3, 5]. Subsequently, HCV
infection is mainly due to risky behaviour, including tattooing, piercing, and sharing conta‐
minated syringes among drug users. Finally, the rate of new infections decreased in the 1990s
with the introduction of anti-HCV blood testing.
Hence, because chronic liver disease may develop many years after acute HCV infection, the
past incidence of acute infections is a major determinant of the future burden of HCV-
associated complications. Projections of the future prevalence of HCV-infected patients
showed that, although the prevalence of HCV infection may be currently declining because of
the decline in incidence in the 1990s, the number of persons infected for the next 20 years could
increase substantially before peaking in 2015 [6].
If the incidence of new HCV infections does not increase in the future, persons born between
1940 and 1965 will be at highest lifetime risk of acquiring the infection [6]. To date, the true
prevalence of HCV infection among elderly residing in nursing homes is largely underesti‐
mated; thus, data from a prospective study demonstrated a high seroprevalence (4,5%) in such
population [7].
3. Natural history and age-related aspects
Given the statement above, we expect an increasing burden of decompensated cirrhosis and
hepatocellular carcinoma (HCC) for the next two decades [1]. People who develop acute
hepatitis C ignore this fact, so recognizing that disease onset is usually based on the potential
circumstance of exposure. Progression into the chronic hepatitis is conventionally defined as
persistence of increased levels of the aminotransferases for 6 months or, more appropriately,
by the confirmation of HCV in the blood beyond that time period. The rate of persistence of
HCV virus after an acute infection varies between several studies [8-11] but, in general, the
HCV-RNA positivity is about 2,5-fold higher in old people than in person aged < 20 years [2].
Evolution from acute to chronic hepatitis mainly occurs in the absence of clinical manifesta‐
tions that become clear only after the liver functions are significantly compromised. Decom‐
pensation of cirrhosis may occur soon or, more usually, several years after cirrhosis is
recognized [12].
However it has been demonstrated in a cohort of patient with a known history of single blood
transfusion in the past, that the period between the age at supposed infection and the devel‐
opment of cirrhosis was shorter if the infection was acquired at an older age [13]. The average
period between the age of infection and the onset of cirrhosis was 33 years in patients who
acquired the HCV infection at the age of 21 to 30, and was reported to decrease to 16 years in
patients who acquired the infection after the age of 40 [13, 14]. Similar findings were demon‐
strated in a Japanese study: the mean time in developing cirrhosis in patients who had a blood
transfusion at the age of 50 or older was reported to be 9.8 years, whereas were 23.6 years in
patients who had a blood transfusion before 50 years [15]. The same study also demonstrated
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that the mean time in developing HCC was 31.5 years against 14.7, depending from receiving
blood transfusion respectively, before or after 50 years [15].
Moving from both findings, we can deduce that when HCV infection is acquired at an old age,
it turns more rapidly into an advanced liver disease, including developing of HCC. Thus, it
has been demonstrated that both patient with chronic HCV infection and HCV-related
cirrhosis will develop an HCC in 1% to 2% of cases per year [3]. In contrast with younger
people, acquiring HCV infection at older age means that complications of cirrhosis, such as
ascitic decompensation, fibrosis and HCC, are often the initial manifestations of hepatitis.
Furthermore, the conjunction of old age at infection, long duration of infection, and aging,
results in a higher risk of rapid fibrosis progression [16]. Liver fibrosis is more pronounced in
elderly than in young people. A study conducted on 6865 patients older than 65 ys demon‐
strated a significant association with age and more intense fibrosis at liver biopsy, regardless
of the duration of infection. Such results corroborate previous modelling, identifying the major
role of aging as an accelerating factor for fibrosis progression after an age of 50 ys [16]. Authors
raised several hypotheses to explain why HCV infection during aging is associated to enhanced
liver fibrogenesis. Animal studies demonstrate in aging liver enhanced hepatic necrosis with
a subsequent exacerbated free radical production and oxidative stress and enhanced suscept‐
ibility of senescent hepatic stellate cells to fibrogenetic stimuli.
Aging is undoubtedly associated with a higher susceptibility to environmental factors,
reduction in the rate of hepatic blood flow and reduced mitochondrial capacity [17]. The
association of Nonalcoholic fatty liver disease (NAFLD) and old age is also a factor that may
contribute to the reduction of mitochondrial reserve, leading to liver deficiency in the presence
of triggering events, such as HCV infection [18]. Taking into account the comorbidity and
polypharmacology of the elderly patient, a good explanation might consider such conditions
as contributor factors both in accelerating liver fibrosis and declining liver function.
Finally, it must also be outlined that immune system function declines with age [19, 20] and
may be responsible for overreaction against HCV infection. With aging, virus T-cell immuno‐
mediated response is impaired due to both a decrease of T-cell function and the ability in
recognizing new antigens [21]. Furthermore, memory subsets T-cell are reduced and cytokine
profile is shifted from Th1 to Th2 leading to a pro-inflammatory response against the antigens
[22, 23]. To sum up, such phenomena belong to the so-called immunosenescence that un‐
doubtedly affects both the severity of liver inflammation and the efficacy of Interferon-based
therapies.
4. HCV treatment in the elderly
The clinical course and management of liver disease in the elderly may differ in several aspects
from those of younger adults. Comorbidities are the main culprits that render elderly patients
more vulnerable to poor drug compliance. Therefore, physicians assign such patients to a
lower priority treatment group, notwithstanding they need treatment since their infection
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advances rapidly. However, this issue is becoming of interest in countries such as Japan and
Italy, where the average age of patients who receive antiviral therapy is about 10-15 years older
than other countries [4, 24].
The efficacy and safety of treating elderly patients remain on debate. Mortality due to liver
failure and HCC is expected to peak after 2030. One way to decrease mortality might be to
extend access to current antiviral therapies and to develop more effective antiviral protocols.
Despite the predictable epidemiological picture, a very limited number of studies have been
dedicated to HCV treatment at old age and most of these have been conducted in the Japanese
and Italian population.
Pegylated interferon (Peg-IFN) plus ribavirin combination therapy has led to a marked
progress in the treatment of chronic C hepatitis [25-27]. However, in aged patients, the antiviral
effect and tolerability to treatment are the main determinants in achieving results [25, 28]. As
previously explained, with aging, development of both liver fibrosis and hepatocellular
carcinoma has been shown to be faster. Accordingly the first goal of treatment of HCV-infected
elderly patients should be HCV elimination [25]. Thus, a treatment strategy, aiming at the
improvement of the antiviral efficacy, should be started as soon as possible.
4.1. Screening and initial assessment
According to the American Association for the Study of Liver Disease (AASLD), persons
who received transfusion of blood or blood products before July 1992 should be checked
for  HCV  infection  [29].  Clinical  statements  about  the  opportunity  of  age-based  HCV
screening  due  to  it's  cost-effective  are  not  clearly  defined  instead  of  current  risk-based
screening practices. However, it is conceivable that people older than 65 year with altera‐
tions in liver function might be screened for HCV infection even in the absence of known/
suspected exposure to HCV.
The diagnosis of chronic hepatitis C is based on the detection of HCV infection (positive
anti-HCV antibodies and HCV RNA) in a patient with signs of chronic hepatitis. Rarely, in
immunosuppressed patients, anti-HCV antibodies are not detected and HCV RNA is present
alone [30]. In order to determine the dose of Ribavirin and treatment decision, the HCV
genotype [1-6] can be determined by various methods, including direct sequence analysis,
reverse hybridization and genotype-specific real-time PCR [30]. Assessment of the severity
of liver disease is recommended before beginning therapy. Liver biopsy, the gold stand‐
ard and more recently, non-invasive methods, including serological markers and transient
elastography  (Fibroscan™,  Echosens),  have  been  extensively  evaluated  in  patients  with
chronic  HCV  infection.  The  accuracy  of  non-invasive  tests  of  liver  fibrosis  is  good  for
identifying patients with mild fibrosis and cirrhosis, but is less reliable for discriminating
moderate and severe fibrosis [31].
In any case, according to the geriatric medicine good practice, treatment decisions should be
tailored on the basis of the severity of the liver disease and presence of comorbidity. Therapy
is contraindicated for patients with decreased life expectancy (< 5 years) due to severe
Practical Management of Chronic Viral Hepatitis188
hypertension, heart failure, or coronary artery disease, poorly controlled diabetes or obstruc‐
tive lung disease [29].
4.2. Individualised therapy for chronic hepatitis c and future perspectives
According to the European Association for the Study of the Liver (EASL), the primary goal of
HCV therapy is to cure the infection, which results in eliminating detectable circulating HCV
after cessation of treatment. Sustained virological response (SVR) is defined as an undetectable
HCV RNA level (<50 IU/ml) 24 weeks after treatment withdrawal. SVR is generally associated
with resolution of liver disease in patients without cirrhosis. The current standard of care (SOC)
for the treatment of chronic hepatitis C and HCV-related compensated cirrhosis is the combi‐
nation of a pegylated IFN and ribavirin.
On the basis of the evidence-based data produced by randomised clinical trials, current
treatment guidelines recommend administering this therapy for 48 weeks to patients infected
by HCV-1 (HCV-1a or HCV-1b) or HCV-4, and for 24 weeks to those infected by HCV-2 or
HCV-3 [30, 32]. The same guidelines recommend stopping antiviral therapy after 12 weeks in
HCV-1 or HCV-4 infected patients if their HCV-RNA levels have not decreased by at least 2
log 10 in comparison with baseline on the basis of solid evidence showing that such patients
have little or no likelihood of achieving a sustained viral response (SVR) when treated for 48–
52 weeks. No similar recommendations have been proposed for patients with HCV-2 and
HCV-3 infection [30, 32].
Two pegylated IFN-α molecules can be used in combination with ribavirin (Peg-IFN α-2a or
Peg-IFN α-2b). The pharmacokinetics of these compounds differs. A large-scale post-approval
US trial comparing various schedules of administration of pegylated interferons with ribavirin
in patients infected with HCV genotype 1 showed no significant difference between the tested
strategies [30]. In contrast, two Italian trials in patients infected with HCV genotypes 1, 2, 3,
and 4 showed some benefit, mostly in genotype 1 patients, in favor of pegylated IFN-α-2a in
combination with ribavirin [30, 33, 34]. Although efficacy is still debated, there is currently no
conclusive evidence that one pegylated IFN-α should be preferred to the other one as first-line
therapy [30].
However, elderly patients with genotype 1 and high HCV loads have a lower SVR rate than
younger patients because of higher dose reduction rates and discontinuation rates due to
ribavirin-related anaemia and others side effects [35]. Reasons for discontinuation of therapy
consisted mainly of anaemia, fatigue, anorexia and depression [35]. In clinical practice, < 15 %
of adults treated with interferon and ribavirin discontinue therapy; however, discontinuation
rates have been reported to be as high as 30 % and dose reductions are required in >70 % of
individuals aged 60 years or older within the first 12 weeks of therapy [1, 36, 37].
The first-line treatment of chronic hepatitis C is based on the use of any of the two pegylated
IFN-α available, administered weekly, subcutaneously, and daily oral ribavirin (evidence
grading according to GRADE system: A1). Schedules and doses are the same as those recom‐
mended for younger patients (GRADE: B3). Pegylated IFN- α-2a should be used at a dose of
180 μg once per week, whereas pegylated IFN- α-2b should be used at a weight-based dose of
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1.5 μg/kg per week. The ribavirin dose depends on the HCV genotype. Patients infected with
HCV genotypes 1 and 4 should receive a weight-based dose of ribavirin: 15 mg/kg body weight
per day. Patients infected with genotypes 2 and 3 can be treated with a flat dose of 800 mg of
ribavirin daily, but those with a BMI beyond 25 or who have baseline factors suggesting low
responsiveness (insulin resistance, metabolic syndrome, severe fibrosis or cirrhosis, older age)
should receive a weight-based dose of ribavirin, similar to genotypes 1 and 4 [30].
Very recently, several progresses have been made in the development of new treatments, such
as new specific inhibitors or direct antiviral agents that are active against hepatitis C virus.
Many studies, mostly conducted in patients infected by HCV genotype 1 who were naïve to
the treatment, showed an increase in the SVR rate of 27–31% [38]. Previous relapse patients
show very high SVR rates of 75%–86%, while response rates are lower for partial responders
(>2 log decline in HCV RNA at 12 weeks of prior therapy) [50–60%) and previous non-
responder patients (33%, data only for telaprevir) [38-40]. Even though there are no data
demonstrating the efficacy and toxicity of such drugs in elderly population, avoid antiviral
therapy due to the advanced age is far from the good practice that should inspire clinicians.
Using the antiviral agents in elderly patients undoubtedly requires special attention to co-
morbid conditions and tolerance for potential side effects. In conclusion, waiting more clinical
studies that will better characterize both the indicators of response and side-effects, we believe
that antiviral therapy should be considered in elderly HCV patients with advanced fibrosis. It
is important to take into account the life expectancy and co-morbidities in the decision of
starting the treatment.
4.3. Treatment monitoring, side effects and stopping rules
According to the EASL Guidelines, patients treated with pegylated IFN-α and ribavirin should
be seen at a minimum of weeks 4 and 12 after initiation of treatment, then, at a minimum of
every 12 weeks until the end of treatment for both efficacy and side effects, and 24 weeks after
the end of therapy to assess the SVR (GRADE: C2). Monitoring of treatment efficacy is based
on repeated measurements of HCV RNA levels. A sensitive, accurate assay with a broad
dynamic range of quantification, ideally a real-time PCR based assay, should be used. The
same assay, ideally from the same laboratory, should be used in each patient to measure HCV
RNA at different time points, in order to assure consistency of results [30].
Before considering typical side effect related to antiviral therapy some consideration are
needed. Elderly have both lower haemoglobin levels and creatinine clearance. Because of a
substantial amount of ribavirin is excreted by kidney, elderly with impaired renal function
may be carefully followed-up. Ribavirin should not be administrated to patients with a
creatinine clearance of < 50 mL/min. Ribavirin should be administered to elderly patients
cautiously, starting at lower dosage, with renal function monitored and dosage adjustments
made accordingly. Note that, in this population, the serum creatinine level might remain
normal as the glomerular filtration rate decreases. Therefore, estimation of creatinine clearance
should be done using equations incorporating age as a variable, such as the Cockroft-Gault
equation [41].
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Furthermore, if Elder have a history of neurological and psychiatric disorders, may be at risk
of neurological side-effects of IFN, such as confusion, lethargy, cognitive changes and
depression [41]. The most frequent side effect developing after 4–6 weeks of therapy due to
the pegylated IFN-α injection, are a flu-like symptoms, which might be easily treated by
paracetamol and paying attention to hydration. Severe fatigue, sleeping disorders, skin
reactions, depression, irritability and dyspnoea may also be related to IFN therapy. Hemato‐
logical and biochemical side effects of pegylated IFN-α and ribavirin include neutropenia,
anaemia, thrombocytopenia, and ALT flares (Tab. 1). These parameters should be assessed at
weeks 1, 2, and 4 of therapy and at 4–8 week intervals thereafter [30].
Frequency IFN-α Ribavirin
Common Flu-like symptoms Haemolysis, dyspepsia
Mild-Uncommon
Depression (mild to severe) Anaemia
Anorexia Myocardial infarction
Thyroid dysfunction Angina
Diabetes Gastrointestinal symptoms
Neuropathy Cough and respiratory symptoms
Leukocytopenia Bacterial infections
Thrombocytopenia Bone marrow aplasia
Table 1. Most frequent side effect of anti viral therapy.
Most studies report a statistically significant higher ribavirin dose reduction and discontinu‐
ation rate in older patients. Based on these data, it would be very interesting knowing whether
a close follow-up of the haemoglobin level could allow a better adjustment of the ribavirin
dose. This strategy should decrease the discontinuation rate observed in the elderly population
and improve the SVR rate. Such approach would take into account the reduction in renal
function and the relative lower level of hemoglobin found in elderly, chronic HCV patients,
making it possible to adapt the dose in relation to the clinical situation of each patient [42].
The pegylated IFN-α dose should be reduced in case of severe side effects, such as clinical
symptoms of severe depression, and if the absolute neutrophil count falls below 750/mm3, or
the platelet count falls below 50,000/mm3. In individual cases, clinicians may choose to
maintain or reduce dosing in these situations but cautious monitoring is advised. When using
pegylated IFN-α-2a, the dose can be reduced from 180 to 135 μg/week and then to 90 μg/week.
When using pegylated IFN-α-2b, the dose can be reduced from 1.5 to 1.0 μg/kg/week and then
to 0.5 μg/ kg/week. Pegylated IFN-α should be stopped in case of marked depression, if the
neutrophil count falls below 500/mm3 or the platelet count falls below 25.000/mm3. If neutro‐
phil or platelet counts go up, treatment can be re-started, but at a reduced pegylated IFN-α
dose. If significant anaemia occurs (haemoglobin <10 g/dl), the dose of ribavirin should be
adjusted downward by 200 mg at a time. Ribavirin administration should be stopped if the
haemoglobin level falls below 8.5 g/dl. Furthermore, treatment should be promptly stopped
in case of a hepatitis flare (ALT levels above 10 times normal, if not already present at the time
Management of HCV Infection in the Elderly
http://dx.doi.org/10.5772/55314
191
of starting treatment) or if a severe bacterial infection occurs at any body site, regardless of
neutrophil counts [30, 43, 44].
Recombinant erythropoietin (EPO) and erythropoiesis-stimulating agents (ESAs) can be
administered when the haemoglobin level falls below 10 g/dl in order to avoid ribavirin dose
reduction or discontinuation (GRADE: C2]. In selected population, such as neoplastic and
diabetic patients, ESAs have been linked to increased risk of serious cardiovascular events,
tumor progression, thrombosis, and death [45]. Nevertheless, using such drugs may help in
managing ribavirin-associated anemia. It is conceivable that clinicians should attend to
traditional thrombosis risk factors in patients prescribed ESAs.
Furthermore, it should be noted that there is no evidence that neutropenia during pegylated
IFN-α and ribavirin therapy is associated with more frequent infection episodes (GRADE: C1),
or that the use of granulocyte colony-stimulating factor (G-CSF) reduces the rate of infections
and/or improves SVR rates (GRADE: B1) [30].
Moreover, patients with a history and/or signs of depression should be seen by a psychiatrist
before therapy and should be treated with antidepressants (GRADE: C2) [30].
In studies using PEG-IFN plus ribavirin the SVR rate is always significantly lower in older
patients than in younger [28, 35, 46]. However SVR depends mainly from HCV genotype.
The study of Antonucci confirmed the effect of age in reducing SVR rate in patients infected
by HCV 1 or 4 genotypes. Furthermore, such study demonstrated that hepatitis due to HCV
genotypes 2 or 3 should be considered for treatment regardless patient’s age suggesting that
optimal  treatment  with  peginterferon  α  plus  ribavirin  may  be  successfully  and  safely
extended to elderly patients with no major contraindications which should be also includ‐
ed in clinical trials [28].
5. Risk of evolution
Several studies have clearly shown that risk of developing an HCC in those who are untreated
is significantly higher than in IFN-treated groups hence, antiviral therapy is an effective way
of reducing such risk and improving survival [47-49]. Interestingly, such observations are
observed, both, from patients in whom SVR has been observed and a biochemical response
obtained.
A retrospective study by Ikeda and colleagues considered the effect of antiviral therapy in a
large cohort of elderly patients with HCV hepatitis. Stratifying patients according to their
platelet count before therapy (high (> 150.000/mm3), intermediate (100.000 – 149.000/mm3) or
low (< 100.000/mm3), authors assessed survival and the risk of hepatocarcinogenesis. The study
demonstrated that hepatocarcinogenesis was significantly and inversely correlated with
platelet count, reflecting the degree of fibrosis. Interferon treatment for a subgroup of elderly
patients with an intermediate or low platelet count conferred substantial advantages with
regard to both hepatocarcinogenesis and survival [47, 50]. Furthermore, the study by Ikeda
and colleagues demonstrates that platelet count can be used as a simple indicator of the risk
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of hepatitis progression. Imai and colleagues, using a conventional interferon-based regimen,
found a significantly lower liver-related mortality rate in elderly patients when compared with
their untreated counterparts [49].
6. Conclusion
There was no rigorous definition of old age and the upper limit for patient age allowed for
interferon-based therapy. Moreover, several aspects should be taken into account; better
stratifying elderly population might help physicians in managing HCV infection, regarding
life expectancy, cost, side effects, and risks caused by interferon-based therapies (Table 2).
Managing chronic HCV infection in elderly
Identify and treat HCV patients before 60 years or as soon as possible
Carefully assess liver health and weigh the benefits-to-risk ratio of antiviral therapy
Treat HCV 2-3 patients more aggressively because of good response of treatment
Tailor the treatment to each patient
Manage side effect more aggressively
Table 2. Recommendation for managing HCV infection in elderly patients.
Furthermore, current guidelines endorse not to suspend antiviral therapy based exclusively
on old age but suggest that special care should be paid to co-morbid conditions and tolerance
for potential side effects [31]. Hence, treatment should be initiated under monitoring if there
are no major contraindications or severe co-morbidities that would compromise the patient’s
life expectancy. Moreover, adverse effects typically resolve spontaneously within 2 – 3 weeks
of discontinuing therapy.
In any case, treatment for the elderly should be individualized. In conclusion, a reduction in
HCC incidence and liver-related deaths are the most desirable endpoints that could be
achieved.
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